Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Andrew McMillan, FRCP, FRCPath, PhD, Kirit M Ardeshna, FRCPath, Jo Gambell, Andrew Jack, PhD, Amy Kirkwood, Anthony Laurie, Silvia Montoto, MD, Shankaranarayana Paneesha, MD, Simon Rule, MD, Russell Patmore, MD, Ruth Pettengell, Humra Shah, Paul Smith, David Linch, FMedSci

Blood (2013) 122 (21): 4348.

https://doi.org/10.1182/blood.V122.21.4348.4348

Published: 2013

Journal Articles

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Bella Patel, MB, BS, MD, A Kirkwood, Aditi Dey, Clare Rowntree, Andrew McMillan, FRCP, FRCPath, PhD, David Marks, MD, PhD, Tobias Menne, Paul Smith, PhD, Simon Purnell, Lynda Micklewright, Adele K Fielding, MB, BS, PhD

Blood (2013) 122 (21): 3900.

https://doi.org/10.1182/blood.V122.21.3900.3900

Published: 2013

Journal Articles

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

Nahid Zareian, Bella Patel, MBBS, FRCPath, Lena Rai-Shetty, PhD, Clare Rowntree, PhD, Andrew McMillan, FRCP, FRCPath, PhD, David I Marks, Tobias Menne, Paul Smith, Simon Purnell, Lynda Micklewright, Anthony V. Moorman, Adele Fielding, MB BS, PhD

Blood (2013) 122 (21): 1335.

https://doi.org/10.1182/blood.V122.21.1335.1335

Published: 2013

Journal Articles

A Single-Centre Series of 40 Patients with Bone-Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia; High Rates of Sustained Response to Oral Methotrexate

Christopher Fox, MBChB, MRCP, FRCPath, Talha Munir, MBBS, MRCP, FRCPath, Ian Carter, Sturch Elaine, Faith Richardson, Andrew McMillan, FRCP, FRCPath, PhD, Simon O'Connor, MBChB, FRCP, FRCPath, Andrew Haynes, MBChB, FRCP, FRCPath

Blood (2012) 120 (21): 3937.

https://doi.org/10.1182/blood.V120.21.3937.3937

Published: 2012

Journal Articles

Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study

David I Marks, MB, BS, PHD, Anthony V Moorman, PhD, Lucy Chilton, Elisabeth Paietta, PhD, Gordon de Wald, Adele K Fielding, MB, BS, PhD, Anthony H. Goldstone, FRCP, FRCPath, Mark R Litzow, MD, Selina M. Luger, MD, Andrew McMillan, FRCP, FRCPath, PhD, Jacob M. Rowe, MD, Martin S Tallman, MD, Hillard M. Lazarus, MD

Blood (2012) 120 (21): 663.

https://doi.org/10.1182/blood.V120.21.663.663

Published: 2012

Journal Articles

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Jonathan I Sive, MBChB, Georgina Buck, Adele Fielding, MBBS, PhD, FRCPath, FRCP, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Susan M Richards, PhD, Jacob M. Rowe, Martin S. Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 493.

https://doi.org/10.1182/blood.V116.21.493.493

Published: 2010

Journal Articles

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial

Adele K. Fielding, MBBS, PhD, FRCPath, FRCP, Georgina Buck, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Anthony V. Moorman, PhD, Elisabeth Paietta, PhD, Susan M Richards, PhD, Martin S. Tallman, MD, Jacob M. Rowe, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 169.

https://doi.org/10.1182/blood.V116.21.169.169

Published: 2010

Journal Articles

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups

Mark R. Litzow, MD, Georgina Buck, Gordon Dewald, Adele Fielding, MBBS, PhD, FRCPath, FRCP, Rhett Ketterling, Hillard M. Lazarus, MD, FACP, Selina Luger, MD, David I. Marks, MBBS, PHD, Andrew McMillan, FRCP, FRCPath, PhD, Anthony V. Moorman, PhD, Elisabeth Paietta, PhD, Susan M Richards, PhD, Jacob M. Rowe, Martin S. Tallman, MD, Anthony H. Goldstone, FRCP, FRCPath

Blood (2010) 116 (21): 524.

https://doi.org/10.1182/blood.V116.21.524.524

Published: 2010

NARROW

Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial

Feasibility Of Pegylated-Asparaginase (PEG-ASP) During Induction In Adults With Acute Lymphoblastic Leukaemia (ALL): Results From The UK Phase 3 Multicentre Trial UKALL 14

Evaluation Of IKZF1 Δ4-7 Deletion As a Suitable Marker For Minimal Residual Disease Monitoring; A Study Of 161 Consecutive Acute Lymphoblastic Leukaemia (ALL) Patients On The On-Going UKALL14 Trial

A Single-Centre Series of 40 Patients with Bone-Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia; High Rates of Sustained Response to Oral Methotrexate

Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study

Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial

Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial

Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference In Results Between B Cell Immunophenotypic Subgroups

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only